Can oral formulation increase the risk of lormetazepam abuse?
Tóm tắt
The slowness of dripping and the presence of alcohol have been offered/suggested as possible causes for the increased risk of developing dependence to the oral formulation of lormetazepam rather than to other anxiolytic and hypnotic drugs. We hence assessed the time of dripping of the most used benzodiazepines and z-drugs oral solution products under experimental conditions and the different employed excipients through a comparative analysis of the Summaries of Product Characteristics. A wide range of the median overall dispensing time was found across the eight products included in the analysis. Among the products containing LMZ, Minias® ranked in the fourth position, while LMZ Mylan Generics® and Noctamid® in the sixth and third, respectively. Our data suggest that the pace of dripping and the presence of alcohol cannot be considered themselves the cause that triggered the abuse of lormetazepam. More precisely, the quantity of alcohol per bottle has been found negligible at therapeutic doses; however, when these are exceeded, they may have clinical implications for patients. Further studies are needed to assess them. Meanwhile, the public-health problem remains and some improvements should be carried out at different levels, to guarantee the appropriate prescription and use of lormetazepam oral solution.
Tài liệu tham khảo
Faccini M, Tamburin S, Casari R et al (2019) High-dose LMZ dependence: strange case of Dr. Jekyll and Mr. Hyde. Intern Emerg Med 14:1271–1278. https://doi.org/10.1007/s11739-019-02101-8
The Medicines Utilisation Monitoring Centre (2020) National Report on Medicines use in Italy. Year 2018.Rome: Italian Medicines Agency, 2019. www.aifa.gov.it. Accessed 5 July 2020
Kapil V, Green JL, Le Lait C et al (2014) Misuse of benzodiazepines and Z-drugs in the UK. Br J Psychiatry 205(5):407–408
Goodman LS, Brunton LL, Chabner B, Knollmann BC (2018) Goodman & Gilman’s pharmacological basis of therapeutics. McGraw-Hill, New York
Cosci F, Nardi AE, Starcevic V et al (2019) LMZ in oral solution: a formulation at risk of high-dose use. Intern Emerg Med 14:1203–1204
Faccini M, Leone R, Pajusco E et al (2012) LMZ addiction: data analysis from an Italian medical unit for addiction. Risk Manag Healthc Policy 5:43–48
Caputo F, Agabio R, Vignoli T et al (2019) Diagnosis and treatment of acute alcohol intoxication and alcohol withdrawal syndrome: position paper of the Italian Society on Alcohol. Intern Emerg Med 14(1):143–160. https://doi.org/10.1007/s11739-018-1933-8
Ansermot N, Griffiths W, Bonnabry P (2002) Detérmination de la fiabilité des flacons compte-gouttes pour l’administration des solutions orales. Miseau point d’un test standardise et application a` des specialités pédiatriques. La Pharmacien Hospitalier 37:233–237
Weaver MF (2015) Prescription Sedative Misuse and Abuse. Yale J Biol Med 88:247–256
Tan KR, Rudolph U (2011) Luscher C Hooked on benzodiazepines: GABAA receptor subtypes and addiction. Trends Neurosci 34:188–197
Ferini-Strambi L, Sforza M, Galbiati A (2020) High-dose lormetazepam dependence: strange case of Dr. Jekyll and Mr. Hyde—comment. Intern Emerg Med 15:341–342. https://doi.org/10.1007/s11739-019-02142-z
Fava GA, Cosci F (2019) Understanding and managing withdrawal syndromes after discontinuation of antidepressant drugs. J Clin Psychiatry. 80(6):19com12794. https://doi.org/10.4088/JCP.19com12794 ((Published 2019 Nov 26))
Dell’Osso B, Albert U, Atti AR, Carmassi C, Carrà G, Cosci F, Del Vecchio V, Di Nicola M, Ferrari S, Goracci A, Iasevoli F, Luciano M, Martinotti G, Nanni MG, Nivoli A, Pinna F, Poloni N, Pompili M, Sampogna G, Tarricone I, Tosato S, Volpe U, Fiorillo A (2015) Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice. Neuropsychiatr Dis Treat 11:1885–1909. https://doi.org/10.2147/NDT.S83130.PMID:26257524;PMCID:PMC4525786
Balon R, Chouinard G, Cosci F, Dubovsky SL, Fava GA, Freire RC, Greenblatt DJ, Krystal JH, Nardi AE, Rickels K, Roth T, Salzman C, Shader R, Silberman EK, Sonino N, Starcevic V, Weintraub SJ (2018) International task force on benzodiazepines. Psychother Psychosom 87:193–194. https://doi.org/10.1159/000489538